HaploX and Xinhe Biologics Forge Strategic Partnership to Accelerate Clinical Translation of mRNA Cancer Vaccines with High-Throughput Sequencing Infrastructure

On June 27, 2025, NeoCura Bio-Medical Technology Co., Ltd. ("NeoCura") and Haplox entered into a strategic partnership.Both parties will integrate their core advantages in gene sequencing technology, biopharmaceutical R&D, and industrialization, jointly promoting the transformation and application of cutting-edge scientific and technological achievements, and injecting strong momentum into industry development and human health.

The signing ceremony was held in Beijing. Dr. Mingyan Xu, founder and CEO of Haplox, and Dr. Wei Li, Executive Vice President of NeoCura, attended and signed on behalf of both parties. The management teams and core technical personnel of both sides witnessed this important moment together.

✦

•

✦

✦

Swipe left or right to view more

✦

Haplox Founder and CEO Dr. Mingyan Xu: "The strategic partnership with NeoCura marks an important milestone for Haplox in deepening its industrial layout and expanding the boundaries of technology application. Breakthrough clinical treatment data released by mRNA vaccine giants such as Moderna and BioNTech signify that RNA technology has moved from 'proof of concept' to 'clinical validation,' while also demonstrating the therapeutic potential of personalized mRNA cancer vaccines. NeoCura is a pioneer in the field of mRNA cancer innovative drug research in China. We are highly anticipating that this collaboration will realize the strategic implementation of 'genomics empowering medical new infrastructure.'"

Dr. Li Wei, Executive Vice President of NeoCura: "Personalized neoantigen vaccines are a 'tailor-made' treatment approach targeting the tumor mutation profile of patients. By combining high-throughput sequencing technology with AI algorithms to screen for patient-specific neoantigens, the integration of AI and mRNA technology can address key challenges and achieve precise targeting of tumors. Haplox's leading capabilities in genetic sequencing and big data analysis are exactly the critical skills that NeoCura urgently needs in its innovative drug development, especially on the path toward precision medicine. This collaboration will significantly enhance the efficiency and accuracy of our target screening, biomarker identification, and patient stratification in clinical trials. We believe that by combining the strengths of both parties, we can accelerate the development of more effective and safer innovative therapies to meet unmet clinical needs. Choosing Haplox is a strategic decision to accelerate innovation and fulfill our mission."

This strategic cooperation is not a simple overlay of businesses but a deep binding based on the highly consistent development concepts and highly complementary core capabilities of both parties.

Haplox will leverage its powerful genetic sequencing and big data analysis platform, advanced multi-omics platform, and strict quality management system to provide critical gene-level data support and analysis services for NeoCura's new drug development. The two companies will complement each other’s strengths and share resources in government research and industrial project applications, jointly promoting collaboration on AI pharmaceuticals and precision medicine projects, as well as the delivery and transformation of high-quality results.

On June 4, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) officially approved the initiation of clinical research for NeoCura's self-developed mRNA personalized tumor neoantigen vaccine XH001.Both parties closely collaborate in clinical research, deeply study the drug efficacy mechanism, and fully accelerate the approval and market launch of revolutionary therapies. They carry out in-hospital research cooperation, share high-quality clinical resources, and efficiently drive the academic output and clinical transformation of mRNA vaccines.

Co-organize online and offline market education activities, brand co-promotion, and professional training to strengthen brand influence and deepen market awareness in AI drug discovery and precision medicine. By integrating resources and taking collaborative actions, jointly cultivate a cooperative ecosystem in the field of precision oncology diagnosis and treatment as well as innovative therapies.